2019 is undoubtedly the year of gene editing. All three major gene editing biotechnology companies have kicked the year off with monumental studies. As the results of these experiments get published, … [Read more...] about Sangamo (NASDAQ: SGMO) Vs. CRISPR Therapeutics (NASDAQ: CRSP): The Best Gene Editing Stock
From designer babies to malaria-resistant mosquitoes, a future where humans can dive into the basic building blocks of all life and manipulate it for our advantage is not too far away. Startups, … [Read more...] about Illumina: Growth at a Fair Price?
Today Adma Biologics (Nasdaq: ADMA) sold off ~10% closing at $3.50. Most of us already in Adma were not phased. Personally, I saw this as a healthy pullback. Since February 1st ADMA has gained 25% … [Read more...] about ADMA Presents Potential Entry For Investors On The Sideline
GALT has updated their NASH-CX presentation. Click here to view the form 8-K and presentation. On March 06, 2019 GALT filed registration statements of a rights offering of common stock and … [Read more...] about GALT Updates NASH-RX Presentation
Amarin (Nasdaq: AMRN) made perhaps the biggest splash in the small-cap biopharmaceutical space last year by announcing trial results from its long-running REDUCE-IT study. The company has a market cap … [Read more...] about Amarin Corporation – A Whale of a Story
Geron Corporation (Nasdaq: GERN) is a clinical stage pharmaceutical company with a current market cap of just over $300 million. Geron has one drug in its pipeline, a telomerase inhibitor called … [Read more...] about Geron: The Neverending Story